Evaxion A-S

Evaxion’s phase‑2 trial extension shows a 75% objective response rate and 92% durable benefit for its AI‑driven melanoma vaccine EVX‑01, promising strong monotherapy and combination efficacy.

Evaxion Biotech has developed an AI-automated vaccine design module that can generate optimized vaccine sequences in real-time, significantly accelerating the vaccine development process from months to days.